Shanghai, China · Founded 2018 · Privately Held (backing)
Developer of gene therapy drugs designed to cure eye diseases. BDGENE is based in Shanghai, China and was founded in 2018. It has raised $40 million.
Last price · $/share
—
Implied valuation
—
Total raised
$40.0M
Last round
—
Cap table — not yet on record
BDGENE's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of BDGENE with a free account
·The complete investor list: 12 names
·Watch BDGENE: the Monday email on marks, rounds and moves
